Juan Carlos Kaski-rekin lankidetzan egindako argitalpenak (22)

2012

  1. Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: A pilot study

    International Journal of Cardiology, Vol. 158, Núm. 1, pp. 160-162

  2. Cardiopulmonary exercise testing for the assessment of exercise capacity in patients with cardiac syndrome X

    International Journal of Cardiology, Vol. 154, Núm. 1, pp. 85-87

  3. Usefulness of serum neopterin levels in acute decompensated heart failure to predict renal dysfunction

    Biomarkers, Vol. 17, Núm. 2, pp. 134-139

2010

  1. Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction

    International Journal of Cardiology, Vol. 144, Núm. 3, pp. 407-409

  2. Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X

    Atherosclerosis, Vol. 213, Núm. 2, pp. 637-641

  3. Melatonin and circadian biology in human cardiovascular disease

    Journal of Pineal Research, Vol. 49, Núm. 1, pp. 14-22

  4. Neopterin predicts left ventricular remodeling in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

    Atherosclerosis, Vol. 211, Núm. 2, pp. 574-578

  5. Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with st-segment elevation myocardial infarction

    American Journal of Cardiology, Vol. 106, Núm. 11, pp. 1540-1544

2009

  1. Disruption of normal circadian rhythms and cardiovascular events

    Heart and Metabolism, pp. 11-15

  2. Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation

    Thrombosis Research, Vol. 123, Núm. 4, pp. 617-621

  3. Inflammatory systemic biomarkers in setting acute coronary syndromes - Effects of the diurnal variation

    Current Drug Targets, Vol. 10, Núm. 10, pp. 1001-1008

  4. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-Effects on soluble CD40 ligand concentrations

    Atherosclerosis, Vol. 206, Núm. 2, pp. 523-527

  5. Melatonina y aterosclerosis coronaria

    Clinica e Investigacion en Arteriosclerosis, Vol. 21, Núm. 5, pp. 247-256

  6. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: Effects of the i f current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome-RIVIERA trial study design and rationale

    Cardiovascular Drugs and Therapy, Vol. 23, Núm. 3, pp. 243-247

  7. Role of ischemia modified albumin to ST-segment resolution after mechanical reperfusion in patients with ST-segment elevation myocardial infarction

    Atherosclerosis, Vol. 203, Núm. 2, pp. 576-580

2008

  1. Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction

    Atherosclerosis, Vol. 199, Núm. 1, pp. 73-78

  2. High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction

    Atherosclerosis, Vol. 196, Núm. 1, pp. 365-371

  3. Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction

    Journal of Pineal Research, Vol. 44, Núm. 1, pp. 65-69

  4. Prognostic Value of Admission Myeloperoxidase Levels in Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock

    American Journal of Cardiology, Vol. 101, Núm. 11, pp. 1537-1540

  5. Relation of ischemia-modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

    Clinica Chimica Acta, Vol. 388, Núm. 1-2, pp. 196-199